Clinical Trial: NCT05397496
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
Status:
ACTIVE NOT RECRUITINGPhase:
Phase 1| Lead Sponsor: | Novartis Pharmaceuticals |
| Information Provided By: | Novartis |
| Last Update Posted: | 2026-07-28 |
Study Overview
Brief Summary
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Official Title
Conditions
Intervention / Treatment
- Biological: PIT565
Other Study ID Numbers
- CPIT565A12101
- 2022-000367-45
Start Date (Actual)
Primary Completion Date (Estimated)
Study Completion Date (Estimated)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | Novartis Pharmaceuticals |
| Information Provided By: | Novartis |
| Last Update Posted: | 2026-07-28 |
Study Overview
Brief Summary
This is an open-label, multicenter, phase I study, which primary objective is to characterize the safety and tolerability of PIT565 and to identify maximal tolerated doses (MTDs) and/or recommended doses (RDs), schedule and route of administration in relapsed and/or refractory B-cell Non-Hodgkin lymphoma (R/R B-NHL) and relapsed and/or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).
Official Title
Conditions
Intervention / Treatment
- Biological: PIT565
Other Study ID Numbers
- CPIT565A12101
- 2022-000367-45